Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 28, 2016
- Accepted in final form April 14, 2017
- First Published July 5, 2017.
Article Versions
- Previous version (July 5, 2017 - 13:03).
- You are viewing the most recent version of this article.
Author Disclosures
- Kate E. Sprecher, MS,
- Rebecca L. Koscik, PhD,
- Cynthia M. Carlsson, MD,
- Henrik Zetterberg, PhD, MD,
- Kaj Blennow, PhD, MD,
- Ozioma C. Okonkwo, PhD,
- Mark A. Sager, MD,
- Sanjay Asthana, MD,
- Sterling C. Johnson, PhD,
- Ruth M. Benca, MD, PhD and
- Barbara B. Bendlin, PhD
- Kate E. Sprecher, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institute on Aging, National Research Service Award F31 AG048732, PI, 2015-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rebecca L. Koscik, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sponsor: NIH Grant Number: R01 AG027161 Role: Collaborator Years: 4/1/13 to 3/31/18
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cynthia M. Carlsson, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I receive research funding from the VA (I01 CX001261), NIH (AG033514), and serve as site PI for the A4 study (funded jointly by NIH and Lilly)
NONE
NONE
I am employed by the Madison VA Hospital. I receive research funding from the VA (I01 CX001261), NIH (AG033514), and serve as site PI for the A4 study (funded jointly by NIH and Lilly)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henrik Zetterberg, PhD, MD,
NONE
NONE
NONE
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor
NONE
NONE
NONE
NONE
NONE
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.
NONE
NONE
(1) The Swedish Research Council (K2010-63P-21562-01-4, K2011-61X-20401-05-6); (2) Swedish State Support for Clinical Research (ALFGBG-144341); (3) VINNOVA; (4) the Knut and Alice Wallenberg Foundation; (5) the European Research Council; and (6) Frimurarestiftelsen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kaj Blennow, PhD, MD,
Dr Blennow has served at advisory boards or as a consultant for Alzheon, Eli Lilly, Fujirebio Europe, IBL International, and Roche Diagnostics.
NONE
NONE
NONE
NONE
NONE
NONE
Novartis
NONE
Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg
NONE
NONE
The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)
NONE
The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.
NONE
NONE
NONE
NONE
NONE
NONE
- Ozioma C. Okonkwo, PhD,
NONE
NONE
NONE
Associate Editor, Journal of Alzheimer's Disease 2017-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. NIH, P50 AG033514-S1, PI, 14 months. 2. NIH, K23 AG045957, PI, 12 months. 3. NIH R21AG051858
NONE
Alzheimer's Association, NIRGD 305257 Extendicare Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Mark A. Sager, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIA RO1 AG 027161, PI, 2007-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sanjay Asthana, MD,
NONE
NONE
NONE
1) Review Editor - Frontiers of Neuroscience; 2009 - Present 2) Associate Editor - Text book, entitled Hazzard's Geriatrics and Gerontology
NONE
Associate Editor - Text book, entitled Hazzard's Geriatric Medicine and Gerontology
NONE
NONE
NONE
NONE
NONE
Received research grant support as a site PI from the following companies to conduct clinical trials in patients with Alzheimer's disease (1) Wyeth Pharmaceutical, (2) Elan Pharmaceutical, (3) Eli Lilly, (4) Pfizer Pharmaceutical, 5) Merck, 6) Lundbeck, 7) Toyoma Chemicals
(1) NIH/NIA 1P50 AG033514-01, PI, 5/01/09-3/31/2014; (2) NIH/NIA 1RO1 AG029624-01, PI, 4/15/07-3/31/2012; (3) NIH/NIA 5KO7 AG021582, PI, 4/15/06-1/31/2011; (4) NIH/NIA 2T32 AG00213-17, PI, 7/1/1991-4/30/2012; (5) NIH/NIA 1RO1 AG027161, Co-I, 4/15/07-3/31/2012; (6) NIH/NIA UO1 AG- 10483 Alzheimer?s Disease Cooperative Study, UW Site PI, 10/1/09-6/30/2012; (7) NIH/NIA UO1 Alzheimer?s Disease Cooperative Study, UW Site PI, 7/1/08-6/30/2011; (8) NIH/NIA UO1 127-01-ADNI-024, UW Site Co-I, 6/1/05- Ongoing; (9) NIH/NIA, NACC Subcontract 5 UO1 AG016976, PI, 7/1/2010-3/31/2014; (10) Department of Veterans Affairs (VA), Office of Academic Affiliations, PI, 12/1/06-open; (11) Department of Veterans Affairs (VA), Cooperative Study Program (CSP), Site PI and Member of the Study Executive Committee, 7/1/07-open; (12) State of Wisconsin, PI, 7/1/05-Recurring; (13) ADCS/NIA studies as a site PI
NONE
John A. Hartford Foundation Role: (PI) Period of Funding: 1/1/08-Present
NONE
NONE
NONE
NONE
NONE
NONE
- Sterling C. Johnson, PhD,
NONE
NONE
NONE
1. Neuropsychology, editorial board member, 2009 to present 2. Journal of the International Neuropsychological Society, editorial board member, 2011 to present 3. Brain Imaging and Behavior, Associate editor
NONE
NONE
NONE
NIH Study Panel member for >10 review sessions of the past two years
NONE
NONE
NONE
NONE
1. NIH R01AG021155, PI, 04-21 2. NIH P50 AG033514, core Leader, 09-19 3. NIH R01AG031790, Coinvestigator, 3 years 4. NIH R01 AG027161, PI, 2014-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ruth M. Benca, MD, PhD and
(1) Merck
NONE
NONE
(1) Sleep, Deputy Editor through December 2006-2016 (2) UpToDate, Section Editor, 2011-present (3) Editor-in-chief, Current Sleep Medicine Reports, 2014-present
NONE
Sleep Disorders: The Clinician's Guide to Diagnosis and Management, Oxford University Press, 2011.
NONE
(1) Janssen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barbara B. Bendlin, PhD
NONE
NONE
NONE
Journal of Alzheimer's Disease; Associate Editor; term ending 12/31/2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) NIH/NIA, Alzheimer's Disease Connectome Project, U01AG051216, 04/01/2016 - 03/31/2020, role: PI 2) NIH/NIA, ADRC Project 2: Midlife Insulin Resistance and obesity: Risk factors for AD-related brain change P50 AG033514 Project, 4/1/2014?3/31/2019, role: PI 3) NIH/NIA, White matter degeneration: biomarkers in preclinical Alzheimer's disease, R01AG037639, 4/1/2012 ? 3/31/2017, role: PI 4) NIH/NIA, Apnea and local sleep: Mechanism and intervention in preclinical Alzheimer's, R56AG052698, 09/30/2016 - 08/31/2017, Role: PI 5) NIH/NIA Diet and Exercise Trial to Improve Insulin Resistance, R21AG053738, 6/1/14 ? 5/31/16, Role: PI 6) NIH/NIA, Wisconsin Alzheimer?s Disease Research Center: NeuroImaging Core, P50 AG033514, 5/1/14 ? 3/31/19 Role: Co-Investigator 7) NIH, Center for Predictive Computational Phenotyping NIH 1U54AI117924, 9/1/14?8/31/19, Role: Project Collaborator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Medicine and Neuroscience Training Program (K.E.S.) and Wisconsin Alzheimer's Disease Research Center (C.M.C., O.C.O., M.A.S., S.A., S.C.J., B.B.B.), University of Wisconsin-Madison; Wisconsin Alzheimer's Institute (R.L.K., C.M.C., O.C.O., M.A.S., S.A., S.C.J., B.B.B.); Geriatric Research Education and Clinical Center (C.M.C., O.C.O., S.A., S.C.J., B.B.B.), Wm. S. Middleton Veterans Hospital, Madison, WI; Institute of Neuroscience and Physiology (H.Z., K.B.), University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square, London, UK; and Department of Psychiatry and Human Behavior (R.M.B.), University of California, Irvine.
- Correspondence to K.E. Sprecher: ksprecher{at}wisc.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.